Top

Published in:

Open Access 01-12-2017 | Research

The predictive value of ¹⁸F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy

Authors: Maria Vittoria Mattoli, Mariangela Massaccesi, Alessandra Castelluccia, Valentina Scolozzi, Giovanna Mantini, Maria Lucia Calcagni

Published in: Radiation Oncology | Issue 1/2017

Abstract

Background

Patients with locally advanced non-small-cell lung cancer (LA-NSCLC) have poor prognosis despite several multimodal approaches. Recently, low-dose fractionated radiotherapy concurrent to the induction chemotherapy (IC-LDRT) has been proposed to further improve the effects of chemotherapy and prognosis. Until now, the predictive value of metabolic response after IC-LDRT has not yet been investigated. Aim: to evaluate whether the early metabolic response, assessed by ¹⁸F-fluoro-deoxyglucose positron emission-computed tomography (¹⁸F-FDG PET-CT), could predict the prognosis in LA-NSCLC patients treated with a multimodal approach, including IC-LDRT.

Methods

Forty-four consecutive patients (35males, mean age: 66 ± 7.8 years) with stage IIIA/IIIB NSCLC were retrospectively evaluated. Forty-four patients underwent IC-LDRT (2 cycles of chemotherapy, 40 cGy twice daily), 26/44 neo-adjuvant chemo-radiotherapy (CCRT: 50.4Gy), and 20/44 surgery. ¹⁸F-FDG PET-CT was performed before (baseline), after IC-LDRT (early) and after CCRT (final), applying PET response criteria in solid tumours (PERCIST). Patients with complete/partial metabolic response were classified as responders; patients with stable/progressive disease as non-responders. Progression free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meyer analysis; the relationship between clinical factors and survivals were assessed using uni-multivariate regression analysis.

Results

Forty-four out of 44, 42/44 and 23/42 patients underwent baseline, early and final PET-CT, respectively. SUL_peak of primary tumour and lymph-node significantly (p = 0.004, p = 0.0002, respectively) decreased after IC-LDRT with a further reduction after CCRT (p = 0.0006, p = 0.02, respectively). At early PET-CT, 20/42 (47.6%) patients were classified as responders, 22/42 (52.3%) as non-responders. At final PET-CT, 19/23 patients were classified as responders (12 responders and 7 non-responders at early PET-CT), and 4/23 as non-responders (all non-responders at early PET-CT). Early responders had better PFS and OS than early non-responders (p ≤ 0.01). Early metabolic response was predictive factor for loco-regional, distant and global PFS (p = 0.02, p = 0.01, p = 0.005, respectively); surgery for loco-regional and global PFS (p = 0.03, p = 0.009, respectively).

Conclusions

In LA-NSCLC patients, ¹⁸F-FDG metabolic response assessed after only two cycles of IC-LDRT predicts the prognosis. The early evaluation of metabolic changes could allow to personalize therapy. This multimodality approach, including both low-dose radiotherapy that increases the effects of induction chemotherapy, and surgery that removes the disease, improved clinical outcomes. Further prospective investigation of this new induction approach is warranted.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.PubMedCrossRef

Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15:4–9.PubMed

Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C, et al. Guidelines on the radical management of patients with lung cancer. Thorax. 2010;65 Suppl 3:iii1–27. doi:10.1136/thx.2010.145938.PubMedCrossRef

National Institute of Health and Clinical Excellence. The diagnosis and treatment of lung cancer. 2011. https://www.nice.org.uk/guidance/cg121.

Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143 Suppl 5:e314S–40. doi:10.1378/chest.12-2360.PubMedCrossRef

Crino L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v103–15. doi:10.1093/annonc/mdq207.PubMedCrossRef

Pallis AG, Gridelli C, van Meerbeeck JP, Greillier L, Wedding U, Lacombe D, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol. 2010;21(4):692–706. doi:10.1093/annonc/mdp360.PubMedCrossRef

Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90. doi:10.1200/JCO.2009.26.2543.PubMedCrossRef

Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer. 2016;96:101–7. doi:10.1016/j.lungcan.2016.04.004.PubMedCrossRef

10.

Mak KS, Gainor JF, Niemierko A, Oh KS, Willers H, Choi NC, et al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015;17(2):296–302. doi:10.1093/neuonc/nou146.PubMedCrossRef

11.

Rami-Porta R, Asamura H, Goldstraw P. Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities. Transl Lung Cancer Res. 2015;4(4):415–23. doi:10.3978/j.issn.2218-6751.2015.07.11.PubMedPubMedCentral

12.

Novello S, Vavalà T, Levra MG, Solitro F, Pelosi E, Veltri A, et al. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Clin Lung Cancer. 2013;14(3):230–7. doi:10.1016/j.cllc.2012.10.004.PubMedCrossRef

13.

Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med. 2007;48(5):744–51.PubMedCrossRef

14.

Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34(4):463–71.PubMedCrossRef

15.

Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21(7):1285–92.PubMedCrossRef

16.

Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer. 2006;107(10):2468–73.PubMedCrossRef

17.

Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2008;62(1):55–61. doi:10.1016/j.lungcan.2008.02.015.PubMedCrossRef

18.

Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(33):8362–70.PubMedCrossRef

19.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50. doi:10.2967/jnumed.108.057307.PubMedPubMedCentralCrossRef

20.

Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e166S–90.PubMedCrossRef

21.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54. doi:10.1007/s00259-014-2961-x.PubMedCrossRef

22.

Dickhoff C, Hartemink KJ, van de Ven PM, van Reij EJ, Senan S, Paul MA, et al. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function. Lung Cancer. 2014;85(2):218–23. doi:10.1016/j.lungcan.2014.06.005.PubMedCrossRef

23.

Nguyen NP, Bishop M, Borok TJ, Welsh J, Hamilton R, Cohen D, et al. Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer Res. 2010;30(3):953–61.PubMed

24.

Albain KS, Swann RS, Rusch VW, Turrisi 3rd AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86. doi:10.1016/S0140-6736(09)60737-6.PubMedPubMedCentralCrossRef

25.

Ding Q, Cheng X, Yang L, Zhang Q, Chen J, Li T, et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). J Thorac Dis. 2014;6(6):677–83. doi:10.3978/j.issn.2072-1439.2014.05.10.PubMedPubMedCentral

26.

Duhaylongsod FG, Lowe VJ, Patz Jr EF, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60(5):1348–52.PubMedCrossRef

27.

Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6(10):3837–44.PubMed

28.

Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36(9):1625–32.PubMed

29.

Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7(4):369–79.PubMedPubMedCentralCrossRef

30.

Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44. doi:10.1016/j.ccm.2011.09.001.PubMedCrossRef

31.

Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer. 2004;45(1):19–27.PubMedCrossRef

32.

Erasmus JJ, McAdams HP, Patz Jr EF, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998;170(5):1369–73.PubMedCrossRef

33.

de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55(1):79–87.PubMedCrossRef

34.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43(11):1954–61.

35.

Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39(6):1016–20.PubMed

36.

Kwee TC, Cheng G, Lam MG, Basu S, Alavi A. SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions. Eur J Nucl Med Mol Imaging. 2013;40(10):1475–7. doi:10.1007/s00259-013-2484-x.PubMedCrossRef

37.

Bufi E, Belli P, Costantini M, Rinaldi P, Di Matteo M, Bonatesta A, et al. MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer. Br J Radiol. 2012;85(1019):e995–1103. doi:10.1259/bjr/31819475.PubMedPubMedCentralCrossRef

38.

Nardone L, Diletto B, De Santis MC, D’ Agostino GR, Belli P, Bufi E, et al. Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study. Breast. 2014;23(5):597–602. doi:10.1016/j.breast.2014.06.005.PubMedCrossRef

39.

Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, et al. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiother Oncol. 2014;113(1):35–40. doi:10.1016/j.radonc.2014.08.014.PubMedCrossRef

40.

Arnold SM, Regine WF, Ahmed MM, Valentino J, Spring P, Kudrimoti M, et al. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys. 2004;58(5):1411–7.PubMedCrossRef

41.

Balducci M, Diletto B, Chiesa S, D’Agostino GR, Gambacorta MA, Ferro M, et al. Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study. Strahlenther Onkol. 2014;190(4):370–6. doi:10.1007/s00066-013-0506-z.PubMedCrossRef

42.

Mantini G, Valentini V, Meduri B, Margaritora S, Balducci M, Micciché F, et al. Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study. Radiother Oncol. 2012;105(2):161–6. doi:10.1016/j.radonc.2012.09.006.PubMedCrossRef

43.

Gupta S, Koru-Sengul T, Arnold SM, Devi GR, Mohiuddin M, Ahmed MM. Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells. Mol Cancer Ther. 2011;10(2):292–302. doi:10.1158/1535-7163.MCT-10-0630.PubMedCrossRef

44.

Dey S, Spring PM, Arnold S, Valentino J, Chendil D, Regine WF, et al. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res. 2003;9(4):1557–65.PubMed

45.

Valentini V, Massaccesi M, Balducci M, Mantini G, Micciché F, Mattiucci GC, et al. Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? Int J Radiat Oncol Biol Phys. 2010;76(2):535–9. doi:10.1016/j.ijrobp.2009.02.075.PubMedCrossRef

46.

Nygård L, Vogelius IR, Fischer BM, Klausen TL, Langer SW, Lonsdale MN, et al. Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiother Oncol. 2016;118(3):460–4. doi:10.1016/j.radonc.2016.01.009.PubMedCrossRef

47.

Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2′-deoxy-2′-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC). J Med Imaging Radiat Oncol. 2016;60(2):231–8. doi:10.1111/1754-9485.12427.PubMedCrossRef

48.

Demaria S, Formenti SC. Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? J Immunother Cancer. 2016;4:29. doi:10.1186/s40425-016-0133-1.PubMedPubMedCentralCrossRef

49.

Schreiner W, Dudek W, Lettmaier S, Gavrychenkova S, Rieker R, Fietkau R, et al. Neoadjuvant radiochemotherapy followed by curative resection in patients with advanced non-small cell lung cancer in stage IIIA/IIIB: prognostic factors and results. Zentralbl Chir. 2016;141(3):323–9. doi:10.1055/s-0042-101558.PubMedCrossRef

50.

Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, et al. Standardized uptake decrease on [18F]-fluorodeoxyglucose positron emission tomography after neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: secondary analysis of a randomized trial for resectable stage IIIA/B non-small-cell lung cancer. J Clin Oncol. 2016. doi:10.1200/jco.2015.65.5167.

51.

Ardizzoni A, Grossi F, Scolaro T, Giudici S, Foppiano F, Boni L, et al. Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. Br J Cancer. 1999;81(2):310–5.PubMedPubMedCentralCrossRef

52.

Calcagni ML, Mattoli MV, Blasi MA, Petrone G, Sammarco MG, Indovina L, et al. A prospective analysis of ¹⁸F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features. Eur J Nucl Med Mol Imaging. 2013;40(11):1682–91. doi:10.1007/s00259-013-2488-6.PubMedCrossRef

53.

Calcagni ML, Taralli S, Cardillo G, Graziano P, Ialongo P, Mattoli MV, et al. Diagnostic performance of (18)F-fluorodeoxyglucose in 162 small pulmonary nodules incidentally detected in subjects without a history of malignancy. Ann Thorac Surg. 2016;101(4):1303–9. doi:10.1016/j.athoracsur.2015.10.072.PubMedCrossRef

Title: The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy
Authors: Maria Vittoria Mattoli
Mariangela Massaccesi
Alessandra Castelluccia
Valentina Scolozzi
Giovanna Mantini
Maria Lucia Calcagni
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-016-0737-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The predictive value of ¹⁸F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Predictors of chest wall toxicity after stereotactic ablative radiotherapy using real-time tumor tracking for lung tumors

Significant suppression of radiation dermatitis in breast cancer patients using a topically applied adrenergic vasoconstrictor

Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation

Correction to: Improved plan quality with automated radiotherapy planning for whole brain with hippocampus sparing: a comparison to the RTOG 0933 trial

Using field size factors to characterize the in-air fluence of a proton machine with a range shifter